Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT04765137
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Mild Cognitive Impairment

Eligibility Criteria

Sex
ALL
Age
60 Years - 95 Years
Healthy Volunteers
Accepted

Interventions

  • Atorvastatin Oral Tablet — DRUG
    Atorvastatin pill 40 mg to be taken every night

Study Details

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

Key Dates

Start date
May 21, 2021
Status verified
Aug 2025
Primary completion
Jul 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atorvastatin 40 mg
    Participants receive 40 mg atorvastatin orally daily in the evening.

Primary Outcome Measure

Change of MRI whole brain cerebrovascular reactivity (wbCVR) [ Time Frame: Baseline and 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins University, Bayview Medical CenterBaltimoreMaryland21224
Samantha Horn
[email protected]
410-550-9020
Ritu Agarwal
[email protected]
410-550-9020
Paul Rosenberg, MD (PRINCIPAL_INVESTIGATOR)
Sevil Yasar, MD, PhD (SUB_INVESTIGATOR)

Find similar trials in Baltimore, MD

By research site
Johns Hopkins University, Bayview Medical Center· Baltimore, MD

Related Studies